Document is current
Any future updates will be listed below
-
Authors
Jerkeman, Mats https://orcid.org/0000-0003-4509-6707
Mellgren, Karin
Sonnevi, Kristina https://orcid.org/0000-0002-7306-2371
Lisak, Mikael
Lagerlöf, Ingemar
Kapas, Balazs
Sjölund, Hanna
Toporski, Jacek https://orcid.org/0000-0001-6012-0651
Hagberg, Hans
Mielke, Stephan
Enblad, Gunilla https://orcid.org/0000-0002-0594-724X
-
Funding
Funding for this research was provided by:
VINNOVA
- License Information
-
More Information
Article History
Received: 15 December 2024
Revised: 16 February 2025
Accepted: 17 March 2025
First Online: 26 March 2025
Competing interests
: MJ has received fees for educational activities and advisory boards arranged by Kite/Gilead and BMS. HH has received fees for training activities and advisory board arranged by Kite/Gilead. GE has received fees for training activities and advisory board arranged by Kite/Gilead. She is the co-founder of SWECARNET: SM has received speaker fees via his institution from Celgene/BMS, Novartis, Janssen, Kite/Gilead, Pfizer, for DSMB activities from Immunicum/Mendes and Miltenyi also via his institution, and Research Funding/CRADA from Kite/Gilead. He is the founder of SWECARNET.
: During this work, all methods were performed in accordance with the relevant guidelines and regulations. Approval was obtained from the Swedish Ethical Review Authority (Dnr 2023-00179-02). Informed consent was obtained from all participants.
